CN114835704B - 作为bcl-2抑制剂的磺酰基苯甲酰胺衍生物 - Google Patents

作为bcl-2抑制剂的磺酰基苯甲酰胺衍生物 Download PDF

Info

Publication number
CN114835704B
CN114835704B CN202210113836.7A CN202210113836A CN114835704B CN 114835704 B CN114835704 B CN 114835704B CN 202210113836 A CN202210113836 A CN 202210113836A CN 114835704 B CN114835704 B CN 114835704B
Authority
CN
China
Prior art keywords
methyl
cancer
mmol
pyridin
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210113836.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN114835704A (zh
Inventor
李东波
陈建勇
刘方
陈浩
查显旵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yasheng Pharmaceutical Group Hong Kong Co ltd
Suzhou Yasheng Pharmaceutical Co ltd
Original Assignee
Yasheng Pharmaceutical Group Hong Kong Co ltd
Suzhou Yasheng Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yasheng Pharmaceutical Group Hong Kong Co ltd, Suzhou Yasheng Pharmaceutical Co ltd filed Critical Yasheng Pharmaceutical Group Hong Kong Co ltd
Publication of CN114835704A publication Critical patent/CN114835704A/zh
Application granted granted Critical
Publication of CN114835704B publication Critical patent/CN114835704B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202210113836.7A 2021-02-01 2022-01-30 作为bcl-2抑制剂的磺酰基苯甲酰胺衍生物 Active CN114835704B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021074709 2021-02-01
CNPCT/CN2021/074709 2021-02-01

Publications (2)

Publication Number Publication Date
CN114835704A CN114835704A (zh) 2022-08-02
CN114835704B true CN114835704B (zh) 2023-10-27

Family

ID=82562087

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210113836.7A Active CN114835704B (zh) 2021-02-01 2022-01-30 作为bcl-2抑制剂的磺酰基苯甲酰胺衍生物

Country Status (5)

Country Link
US (1) US12577245B2 (https=)
EP (1) EP4298098A4 (https=)
JP (1) JP2024504542A (https=)
CN (1) CN114835704B (https=)
WO (1) WO2022161496A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024032776A1 (en) * 2022-08-12 2024-02-15 Fochon Biosciences, Ltd. Compounds as bcl-2 inhibitors

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1906183A (zh) * 2003-11-13 2007-01-31 艾博特公司 N－酰基磺酰胺细胞程序死亡促进剂
CN102307872A (zh) * 2008-12-05 2012-01-04 雅培制药有限公司 作为用于治疗癌症和免疫疾病的bcl-2-选择性诱发细胞凋亡药剂的磺酰胺衍生物
CN102947283A (zh) * 2010-03-25 2013-02-27 Abbvie公司 用于治疗癌症和免疫以及自身免疫性疾病的细胞凋亡诱导剂
CN108658983A (zh) * 2017-06-26 2018-10-16 深圳市塔吉瑞生物医药有限公司 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
CN110177788A (zh) * 2017-01-07 2019-08-27 上海复尚慧创医药研究有限公司 作为bcl-2选择性凋亡诱导剂的化合物
WO2019185025A1 (zh) * 2018-03-30 2019-10-03 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂
CN110483501A (zh) * 2016-08-05 2019-11-22 密歇根大学董事会 作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物
WO2020088442A1 (zh) * 2018-10-29 2020-05-07 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂
WO2020238785A1 (zh) * 2019-05-24 2020-12-03 正大天晴药业集团股份有限公司 包括甲基和三氟甲基的双取代磺酰胺类选择性bcl-2抑制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN113444078B (zh) * 2020-03-25 2023-07-07 中国科学院上海有机化学研究所 抗凋亡蛋白Bcl-2抑制剂及其制备方法和应用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1906183A (zh) * 2003-11-13 2007-01-31 艾博特公司 N－酰基磺酰胺细胞程序死亡促进剂
CN102307872A (zh) * 2008-12-05 2012-01-04 雅培制药有限公司 作为用于治疗癌症和免疫疾病的bcl-2-选择性诱发细胞凋亡药剂的磺酰胺衍生物
CN102947283A (zh) * 2010-03-25 2013-02-27 Abbvie公司 用于治疗癌症和免疫以及自身免疫性疾病的细胞凋亡诱导剂
CN110483501A (zh) * 2016-08-05 2019-11-22 密歇根大学董事会 作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物
CN110177788A (zh) * 2017-01-07 2019-08-27 上海复尚慧创医药研究有限公司 作为bcl-2选择性凋亡诱导剂的化合物
CN108658983A (zh) * 2017-06-26 2018-10-16 深圳市塔吉瑞生物医药有限公司 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
WO2019185025A1 (zh) * 2018-03-30 2019-10-03 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂
WO2020088442A1 (zh) * 2018-10-29 2020-05-07 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂
WO2020238785A1 (zh) * 2019-05-24 2020-12-03 正大天晴药业集团股份有限公司 包括甲基和三氟甲基的双取代磺酰胺类选择性bcl-2抑制剂

Also Published As

Publication number Publication date
US20240166644A1 (en) 2024-05-23
US12577245B2 (en) 2026-03-17
JP2024504542A (ja) 2024-02-01
EP4298098A1 (en) 2024-01-03
EP4298098A4 (en) 2025-06-25
WO2022161496A1 (en) 2022-08-04
CN114835704A (zh) 2022-08-02

Similar Documents

Publication Publication Date Title
JP7205903B2 (ja) Ｂｃｌ－２阻害剤としてのｎ－（フェニルスルホニル）ベンズアミドおよび関連化合物
CN110914265B (zh) 作为lsd-1抑制剂的吡咯并[2,3-c]吡啶和相关类似物
CN109715620B (zh) 作为alk抑制剂的氨基嘧啶
AU2019356772A1 (en) Small molecule MDM2 protein degraders
CN110294750A (zh) 作为alk抑制剂的5,6-二氢-11h-吲哚并[2,3-b]喹啉-11-酮化合物
TW202003465A (zh) 作為共價menin抑制劑之六氫吡啶化合物
CN119730847A (zh) Nrf2蛋白降解剂
CN114835704B (zh) 作为bcl-2抑制剂的磺酰基苯甲酰胺衍生物
CN115490708B (zh) 磺酰胺类大环衍生物及其制备方法和用途
HK40001439B (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
HK40001439A (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
HK40012150A (en) 5,6-dihydro-11h-indolo[2,3-b]quinolin-11-one compounds as alk inhibitors
HK40019323B (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
HK40019323A (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
HK40041770A (en) Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors
HK40041770B (en) Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors
BR112019001666B1 (pt) Compostos de n-(fenilsulfonil)benzamidas e sais e solvatos dos mesmos, composições farmacêuticas e seus usos no tratamento de doenças, distúrbios ou afecções através da inibição de bcl-2
HK40007649B (en) Aminopyrimidines as alk inhibitors
HK40007649A (en) Aminopyrimidines as alk inhibitors
HK40001725A (en) N-(phenylsulfonyl)benzamide derivatives as bcl-2 inhibitors
HK40001725B (en) N-(phenylsulfonyl)benzamide derivatives as bcl-2 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: No. 68, Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu

Applicant after: Suzhou Yasheng Pharmaceutical Co.,Ltd.

Applicant after: Yasheng Pharmaceutical Group (Hong Kong) Co.,Ltd.

Address before: Unit 701, Building B7, No. 218, Xinghu Street, Suzhou Industrial Park, Suzhou City, Jiangsu Province, 215000

Applicant before: Suzhou Yasheng Pharmaceutical Co.,Ltd.

Applicant before: Yasheng Pharmaceutical Group (Hong Kong) Co.,Ltd.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant